Company and Stock Identity

How NextStage Clinical Research Connects to the Public Market

Company structure
Private company, not independently verified
Market access
No current public listing was verified.
Research focus
What is known here is a sale, and a sale tells you something. A company that builds research sites inside physician practices and then sells three of them is either focusing or retreating, and the announcement does not say which. Because the company publishes nothing this desk can read, treat any description of its remaining size or locations as unverified until NextStage states it somewhere readable. If you need the terms of the Texas deal, look for them through the buyer rather than the seller.

This is an honest gap, not a finding. The nextstageclinical.com server refused a secure connection to this desk on 2026-11-14, failing the TLS handshake from two different networks and from two different operating systems, so no page on the company's own site could be read at all. Every fact in this profile therefore comes from pages that did open. The Iterative Health announcement of 14 May 2026 names NextStage Clinical Research as the seller of three cardiology research sites in Beaumont, Port Arthur and Waco, Texas. The Waco Tribune-Herald report carried on the same newsroom, dated 8 June 2026, describes those sites as previously operated by NextStage. No listing, parent, legal name or share structure could be confirmed, so this record claims none. Checked on 2026-11-14.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Iterative Health ... Company source

Iterative Health buys three Texas cardiology research sites from NextStage Clinical Research

Iterative Health said on 14 May 2026 that it had acquired three cardiology research sites from NextStage Clinical Research, located in Beaumont, Port Arthur and Waco, Texas. Jonathan Ng, founder and chief executive of Iterative Health, is quoted calling the established sites a key addition as the company builds out its cardiology focus within its global network. Donald S. Cross, a cardiologist and principal investigator at Waco Cardiology Associates, is quoted calling the move a natural next step for the site staff and the patients they serve. The announcement states no purchase price and no other financial terms. A later Waco Tribune-Herald report carried on the same newsroom, dated 8 June 2026, adds that the Waco research operation had 200 to 250 trial participants enrolled.

Why it matters: This is a company buying the thing it used to sell software to. Iterative Health has been measuring trials with AI; owning the sites means it now controls enrolment, the scarcest resource in clinical research, and can promise a sponsor patients rather than tools. It also moves the company into cardiology, a long way from the gut disease work it is known for. The risk sits in the same place as the value. A research site is mostly its principal investigator and the patients who trust that person, and neither is a transferable asset. The quote from the Waco investigator reads as a signal that the staff are staying, which is exactly what a buyer needs, but it is a statement of intent made on the day of the deal. With no price disclosed, there is also no way to judge what the company paid for 200 to 250 enrolled patients, which is the number that makes a site worth owning.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: This is an honest gap. No page on the company's own site could be reached on 2026-11-14 because the server refused a secure connection, so no role list, location count or team size could be read. No careers link is given here rather than one this desk has not opened. Treat this field as unread rather than empty.

Qualification signal: The model described in the acquisition announcement is research run inside a working physician practice, which is a different job from research run in a dedicated trial centre. The experience that matters is enrolling patients without disrupting a clinic that still has to see them. Because no role list could be read, do not guess from a job title; ask which practice a role sits inside and who employs the clinical staff.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Trial sponsors, research site leaders, physician group executives weighing a research partnership, and investors reading a site network roll up
Primary use case
Host and staff clinical trials inside a community medical practice, and enrol patients who would otherwise never be offered a study
Typical deployment
Physician practice, specialty group, or research site operator. AI arrives through a sponsor or a research network partner rather than through a software purchase.

Evidence questions

  • How many of the named sites are actively enrolling patients right now, rather than contracted?
  • Who measured the enrolment result, the network or the sponsor paying for it?
  • Did patient volume survive the acquisition, or did the investigators leave with it?

Regulatory and workflow questions

  • Who holds the regulatory responsibility for the study at each site after an acquisition?
  • Which review board oversees the trials, and did it change when ownership changed?
  • How is informed consent handled when a practice becomes part of a research network?

Data and contract questions

  • Which patient data leave the practice, who receives them, and in what form?
  • Can the practice still see the study results it helped produce?
  • What happens to the research data if the network is sold again?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources